AEON Biopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
AEON Biopharma, Inc. (AEON) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.30% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-30
- AEON Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.30%, a 17.49% increase year-over-year.
- AEON Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 3.66%.
- AEON Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.30%, a 2.27% decline from fiscal 2023.
- AEON Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.40%, a 12.24% increase from fiscal 2022.
- AEON Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.92%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2024-12-31 | 4.30% 10-K · filed 2026-03-30 | |||
| 2024-09-30 | 4.30% 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | 4.30% 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | 4.30% 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | 4.40% 10-K · filed 2025-03-24 | |||
| 2023-09-30 | 4.40% 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | 3.66% 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | 3.66% 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 3.92% 10-K/A · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |